1. Home
  2. KRYS vs CBT Comparison

KRYS vs CBT Comparison

Compare KRYS & CBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRYS
  • CBT
  • Stock Information
  • Founded
  • KRYS 2015
  • CBT 2019
  • Country
  • KRYS United States
  • CBT United States
  • Employees
  • KRYS N/A
  • CBT N/A
  • Industry
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • CBT Major Chemicals
  • Sector
  • KRYS Health Care
  • CBT Industrials
  • Exchange
  • KRYS Nasdaq
  • CBT Nasdaq
  • Market Cap
  • KRYS 3.8B
  • CBT 4.0B
  • IPO Year
  • KRYS 2017
  • CBT N/A
  • Fundamental
  • Price
  • KRYS $143.08
  • CBT $78.37
  • Analyst Decision
  • KRYS Strong Buy
  • CBT Hold
  • Analyst Count
  • KRYS 9
  • CBT 3
  • Target Price
  • KRYS $208.78
  • CBT $92.67
  • AVG Volume (30 Days)
  • KRYS 374.0K
  • CBT 378.1K
  • Earning Date
  • KRYS 08-04-2025
  • CBT 08-04-2025
  • Dividend Yield
  • KRYS N/A
  • CBT 2.30%
  • EPS Growth
  • KRYS 109.01
  • CBT N/A
  • EPS
  • KRYS 4.16
  • CBT 7.72
  • Revenue
  • KRYS $333,448,000.00
  • CBT $3,908,000,000.00
  • Revenue This Year
  • KRYS $44.05
  • CBT N/A
  • Revenue Next Year
  • KRYS $46.15
  • CBT $3.55
  • P/E Ratio
  • KRYS $34.43
  • CBT $10.15
  • Revenue Growth
  • KRYS 247.53
  • CBT N/A
  • 52 Week Low
  • KRYS $122.80
  • CBT $71.64
  • 52 Week High
  • KRYS $219.34
  • CBT $117.46
  • Technical
  • Relative Strength Index (RSI)
  • KRYS 57.50
  • CBT 59.14
  • Support Level
  • KRYS $135.86
  • CBT $74.57
  • Resistance Level
  • KRYS $143.44
  • CBT $76.93
  • Average True Range (ATR)
  • KRYS 5.15
  • CBT 1.63
  • MACD
  • KRYS 1.07
  • CBT 0.49
  • Stochastic Oscillator
  • KRYS 80.33
  • CBT 82.81

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About CBT Cabot Corporation

Cabot Corp manufactures and sells a variety of chemicals, materials, and chemical-based products. The company organizes itself into the following operating segments based on the product type; the Reinforcement Materials segment which generates maximum revenue provides reinforcing carbon products used in tires, and industrial products such as hoses, belts, extruded profiles, and molded goods; and the Performance Chemicals segment aggregates the specialty carbons, specialty compounds, fumed metal oxides, battery materials, inkjet colorants, and aerogel product lines. Geographically, the company derives maximum revenue from its customers in Europe, the Middle East, and Africa and the rest from the Americas and Asia Pacific region.

Share on Social Networks: